Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months
Portfolio Pulse from charles@benzinga.com
Cellectar Biosciences' Iopofosine I 131 has exceeded its primary endpoint in a pivotal study for Waldenstrom's Macroglobulinemia, achieving a 56.4% major response rate and a 98.2% disease control rate in heavily pretreated patients.
July 23, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectar Biosciences' Iopofosine I 131 has shown promising results in a pivotal study for Waldenstrom's Macroglobulinemia, exceeding the primary endpoint with a 56.4% major response rate and achieving a 98.2% disease control rate in heavily pretreated patients.
The positive results from the pivotal study are likely to boost investor confidence in Cellectar Biosciences, potentially driving the stock price up in the short term. The high response and disease control rates in a difficult-to-treat patient population highlight the efficacy of Iopofosine I 131, making it a significant development for the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100